This is the authors' abstract. We don't add key points for this paper.
Our study has shown that the HER2-low phenotype is common among hormone-positive patients. The clinicopathological features and prognostic data indicate that the hormonal receptors effect and HER2 heterogeneity are crucial factors to consider. It is important to note that this particular subgroup is different from the HER2-negative one and should not be treated in the same way. Therefore, this study offers a new perspective in the management of HER2-low patients and can serve as a basis for future prospective analyses.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gamrani et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: